At ADA26, Pfizer added additional framing for berobenatide’s use in obesity and diabetes, citing data presented alongside its long-acting GLP-1 receptor agonist program. The coverage also ties the update to Pfizer’s acquisition of Metsera, with the company signaling that the monthly regimen could extend efficacy across populations that respond differently to incretin-based therapies.